Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients

Inclusion Criteria: * HIV-1 infected adults, * age ≥ 18 years, * with a once-a-day ritonavir-boosted darunavir 800mg/j containing regimen plus 2 NRTI (≥ 6 months), * virologically controlled (VL ≤ 50 cp/ml, * ≥ 1 year, * at least 2 VL spaced at least 3 months apart in the last 12 months) CD4 count ≥ 300/mm3 ≥ 6 months, * virus sensible to darunavir and the used NRTI (pretreatment resistance genotypic test available) and * with no history of virological failure (VL \> 200 cp/mL after ≥ 6 months under PI and/or used NRTI), * no current opportunistic infection, * renal clearance ≥ 60 mL/min if tenofovir is used, * transaminases (SGOT, SGPT) plasma levels \< 2N, * hemoglobin \> 11 g/dL, * platelets count \> 150 000/mm3, * negative pregnancy test in women with childbearing potential, * informed written consent signed by both the investigator and the subject, * national insurance scheme (article L1121-11 of the French Public Health code), * no participation to any other clinical trial Exclusion Criteria: * HIV-2 infection, * current antiretroviral therapy different from a once-a-day ritonavir-boosted darunavir 800mg/j containing regimen plus 2 NRTI, * virus genotypically resistant to darunavir and the used NRTIs, * history of virological failure (VL \> 200 cp/mL after ≥ 6 months under PI and/or used NRTI), * irregular follow-up and/or history of lack of adherence to ART ≤ 12 months, * current pregnancy, * current opportunistic infection, * associated treatment containing one or more drugs interacting with hepatic cytochromes, * any addictive behaviors (alcohol consumption, drugs …) likely to jeopardize the safety of the treatment and / or patient compliance and adherence to the trial.